CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 54 enrolled
Drug / intervention
Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00527592
NCT00527592Phase 4Completed

A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Alcon Research·interventional·Posted Sep 11, 2007·Updated May 18, 2012

In Brief

A Phase 4 clinical trial evaluating Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®) and Latanoprost ophthalmic solution 0.005% (XALATAN®) for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 54 participants.

Detailed Summary

The purpose of this study is to compare the comfort of Travatan Z in one eye and Xalatan in the opposite eye in patients with primary open-angle glaucoma or ocular hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 11, 2007
Enrollment StartMay 1, 2007
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.8 years ago

Interventions

Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)drug

Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as travoprost.

Latanoprost ophthalmic solution 0.005% (XALATAN®)drug

Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as latanoprost.